Richard A. Scolyer

111.9k total citations · 12 hit papers
707 papers, 30.6k citations indexed

About

Richard A. Scolyer is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Richard A. Scolyer has authored 707 papers receiving a total of 30.6k indexed citations (citations by other indexed papers that have themselves been cited), including 557 papers in Oncology, 307 papers in Molecular Biology and 132 papers in Immunology. Recurrent topics in Richard A. Scolyer's work include Cutaneous Melanoma Detection and Management (377 papers), Melanoma and MAPK Pathways (208 papers) and Cancer Immunotherapy and Biomarkers (150 papers). Richard A. Scolyer is often cited by papers focused on Cutaneous Melanoma Detection and Management (377 papers), Melanoma and MAPK Pathways (208 papers) and Cancer Immunotherapy and Biomarkers (150 papers). Richard A. Scolyer collaborates with scholars based in Australia, United States and Netherlands. Richard A. Scolyer's co-authors include John F. Thompson, Georgina V. Long, Richard Kefford, Alexander M. Menzies, James S. Wilmott, Rajmohan Murali, Lauren E. Haydu, Stanley W. McCarthy, Robyn P.M. Saw and Matteo S. Carlino and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Richard A. Scolyer

675 papers receiving 30.2k citations

Hit Papers

Melanoma staging: Evidence‐based changes in the Amer... 2011 2026 2016 2021 2017 2011 2018 2012 2011 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
    2017 1.4k citations Richard A. Scolyer, Vernon K. Sondak et al. profile →
  2. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
    2011 794 citations Georgina V. Long, Alexander M. Menzies et al. profile →
  3. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
    2018 655 citations Georgina V. Long, Serigne Lo et al. profile →
  4. Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma
    2012 606 citations Richard A. Scolyer, Marc Moncrieff et al. profile →
  5. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
    2011 507 citations James S. Wilmott, Georgina V. Long et al. Clinical Cancer Research profile →
  6. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
    2012 470 citations Richard A. Scolyer, Georgina V. Long et al. profile →
  7. Resistance to PD1/PDL1 checkpoint inhibition
    2016 429 citations Georgina V. Long, Richard A. Scolyer et al. profile →
  8. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
    2019 412 citations Tuba N. Gide, Camelia Quek et al. Clinical Cancer Research profile →
  9. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention
    2015 390 citations Richard A. Scolyer, Diona L. Damian et al. profile →
  10. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
    2014 382 citations Alexander M. Menzies, Matteo S. Carlino et al. Clinical Cancer Research profile →
  11. Cutaneous melanoma
    2023 350 citations Georgina V. Long, Alexander M. Menzies et al. The Lancet profile →
  12. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway
    2020 304 citations David E. Elder, Richard A. Scolyer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard A. Scolyer Australia 84 21.3k 13.3k 6.6k 4.3k 4.1k 707 30.6k
Alexander M.M. Eggermont Netherlands 72 18.5k 0.9× 9.4k 0.7× 6.7k 1.0× 2.7k 0.6× 3.5k 0.9× 389 25.8k
Klaus J. Busam United States 80 16.6k 0.8× 9.3k 0.7× 4.2k 0.6× 2.7k 0.6× 3.2k 0.8× 426 24.8k
Keith T. Flaherty United States 92 24.8k 1.2× 23.3k 1.8× 7.1k 1.1× 5.7k 1.3× 2.5k 0.6× 518 39.7k
Jeffrey E. Gershenwald United States 72 19.6k 0.9× 9.8k 0.7× 5.0k 0.8× 2.6k 0.6× 5.7k 1.4× 283 25.5k
Vernon K. Sondak United States 71 16.6k 0.8× 8.3k 0.6× 5.7k 0.9× 1.5k 0.4× 3.4k 0.8× 432 22.6k
Michael B. Atkins United States 91 25.3k 1.2× 16.0k 1.2× 12.0k 1.8× 6.3k 1.5× 3.5k 0.9× 577 40.7k
Kelly M. McMasters United States 69 15.0k 0.7× 6.3k 0.5× 3.4k 0.5× 4.5k 1.0× 5.1k 1.3× 434 23.5k
Georgina V. Long Australia 85 25.4k 1.2× 16.6k 1.2× 9.2k 1.4× 3.5k 0.8× 1.8k 0.4× 684 34.4k
Paolo A. Ascierto Italy 75 18.1k 0.8× 11.4k 0.9× 7.1k 1.1× 2.5k 0.6× 1.8k 0.4× 757 25.2k
Donald L. Morton United States 86 22.7k 1.1× 10.4k 0.8× 8.8k 1.3× 4.0k 0.9× 6.8k 1.7× 448 33.4k

Countries citing papers authored by Richard A. Scolyer

Since Specialization
Citations

This map shows the geographic impact of Richard A. Scolyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Scolyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Scolyer more than expected).

Fields of papers citing papers by Richard A. Scolyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard A. Scolyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Scolyer. The network helps show where Richard A. Scolyer may publish in the future.

Co-authorship network of co-authors of Richard A. Scolyer

This figure shows the co-authorship network connecting the top 25 collaborators of Richard A. Scolyer. A scholar is included among the top collaborators of Richard A. Scolyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard A. Scolyer. Richard A. Scolyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schadendorf, Dirk, Jason J. Luke, Paolo A. Ascierto, et al.. (2024). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for ImmunoTherapy of Cancer. 12(3). e007501–e007501. 5 indexed citations
2.
Versluis, Judith M., Petros Dimitriadis, James S. Wilmott, et al.. (2024). Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma. Journal for ImmunoTherapy of Cancer. 12(4). e008125–e008125. 9 indexed citations
3.
Long, Georgina V., Matteo S. Carlino, George Au‐Yeung, et al.. (2024). Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial. Nature Medicine. 30(9). 2540–2548. 15 indexed citations
4.
Lo, Serigne, Gabrielle Williams, Anne Ε. Cust, et al.. (2024). Long-term survival across Breslow thickness categories: findings from a population-based study of 210 042 Australian melanoma patients. JNCI Journal of the National Cancer Institute. 117(1). 152–156. 4 indexed citations
5.
Reijers, Irene L. M., Petros Dimitriadis, Alexander M. Menzies, et al.. (2023). 1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma. Annals of Oncology. 34. S660–S660. 2 indexed citations
6.
Gide, Tuba N., Nurudeen A. Adegoke, Camelia Quek, et al.. (2023). Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach. Journal of Translational Medicine. 21(1). 257–257. 6 indexed citations
7.
London, Kevin, Alison J. Potter, Serigne Lo, et al.. (2022). Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. Melanoma Research. 32(4). 260–268. 1 indexed citations
8.
Moncrieff, Marc, Serigne Lo, Richard A. Scolyer, et al.. (2022). Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. Annals of Surgical Oncology. 29(9). 5937–5945. 10 indexed citations
9.
Reijers, Irene L. M., Robert V. Rawson, Andrew J. Colebatch, et al.. (2022). Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. JAMA Surgery. 157(4). 335–335. 25 indexed citations
10.
Griewank, Klaus, Christian Koelsche, Johannes A.P. van de Nes, et al.. (2018). Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. Clinical Cancer Research. 24(18). 4494–4504. 24 indexed citations
11.
Lo, Serigne, et al.. (2016). Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases. British Journal of Dermatology. 175(6). 1290–1300. 42 indexed citations
12.
Busam, Klaus J., Ricardo E. Vilain, Trina Lum, et al.. (2016). Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation. The American Journal of Surgical Pathology. 40(6). 786–795. 39 indexed citations
13.
14.
Haydu, Lauren E., Richard A. Scolyer, Andrew J. Spillane, et al.. (2015). Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1–2 mm in Thickness): Analysis of 2131 Patients Treated at a Single Center. Annals of Surgical Oncology. 23(4). 1071–1081. 22 indexed citations
15.
Ploeg, Augustinus P. T. van der, Lauren E. Haydu, Andrew J. Spillane, et al.. (2014). Outcome Following Sentinel Node Biopsy Plus Wide Local Excision Versus Wide Local Excision Only for Primary Cutaneous Melanoma. Annals of Surgery. 260(1). 149–157. 29 indexed citations
16.
Cho, Eunae Sandra, Fergal J. Moloney, Hong Cai, et al.. (2013). Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). The Lancet. 381(9880). 1835–1843. 84 indexed citations
17.
Cho, Eunae Sandra, Hong Cai, Hendrik‐Tobias Arkenau, et al.. (2013). Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER). DSpace@MIT (Massachusetts Institute of Technology). 1 indexed citations
18.
Marzese, Diego M., Richard A. Scolyer, Sharon K. Huang, et al.. (2013). Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Molecular Genetics. 23(1). 226–238. 83 indexed citations
19.
Barnhill, Raymond L., Lorenzo Cerroni, Martin Cook, et al.. (2010). State of the Art, Nomenclature, and Points of Consensus and Controversy Concerning Benign Melanocytic Lesions: Outcome of an International Workshop. Advances in Anatomic Pathology. 17(2). 73–90. 46 indexed citations
20.
Scolyer, Richard A., Jonathan R. Stretch, S W McCarthy, & John L.P. Thompson. (2005). Collaboration between clinicians and pathologists: a necessity for the optimal management of melanoma patients. Cancer Forum. 29(2). 76. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander M.M. Eggermont Breakdown of academic impact, for papers by Klaus J. Busam Breakdown of academic impact, for papers by Keith T. Flaherty Breakdown of academic impact, for papers by Jeffrey E. Gershenwald Breakdown of academic impact, for papers by Vernon K. Sondak Breakdown of academic impact, for papers by Michael B. Atkins Breakdown of academic impact, for papers by Kelly M. McMasters Breakdown of academic impact, for papers by Georgina V. Long Breakdown of academic impact, for papers by Paolo A. Ascierto Breakdown of academic impact, for papers by Donald L. Morton
Rankless by CCL
2026